Keros Therapeutics, Inc.
KROS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,550 | $151 | $0 | $20,100 |
| % Growth | 2,251% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3,550 | $151 | $0 | $20,100 |
| % Margin | 100% | 100% | – | 100% |
| R&D Expenses | $173,629 | $135,258 | $87,265 | $55,143 |
| G&A Expenses | $40,754 | $34,834 | $27,525 | $21,330 |
| SG&A Expenses | $40,754 | $34,834 | $27,525 | $21,330 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $214,383 | $170,092 | $114,790 | $76,473 |
| Operating Income | -$210,833 | -$169,941 | -$114,790 | -$56,373 |
| % Margin | -5,939% | -112,543.7% | – | -280.5% |
| Other Income/Exp. Net | $23,780 | $16,949 | $10,111 | -$360 |
| Pre-Tax Income | -$187,053 | -$152,992 | -$104,679 | -$56,733 |
| Tax Expense | $300 | $0 | $0 | $2,011 |
| Net Income | -$187,353 | -$152,992 | -$104,679 | -$58,744 |
| % Margin | -5,277.5% | -101,319.2% | – | -292.3% |
| EPS | -5 | -5.2 | -4.15 | -2.52 |
| % Growth | 3.8% | -25.3% | -64.7% | – |
| EPS Diluted | -5 | -5.2 | -4.15 | -2.52 |
| Weighted Avg Shares Out | 37,438 | 29,447 | 25,241 | 23,334 |
| Weighted Avg Shares Out Dil | 37,438 | 29,447 | 25,241 | 23,334 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $1 | $4 |
| Depreciation & Amortization | $1,229 | $815 | $674 | $378 |
| EBITDA | -$185,824 | -$152,177 | -$104,004 | -$56,351 |
| % Margin | -5,234.5% | -100,779.5% | – | -280.4% |